PharmaShots | Incisive News in 3 Shots

Subscribe Now

ASLAN

ASLAN Reports First Patient Enrollment in P-IIb (TREK-AD) Study of ASLAN004 (eblasakimab) for the Treatment of Atopic Dermatitis

ASLAN Reports First Patient Enrollment in P-IIb (TREK-AD) Study of ASLAN004 (eblasakimab) for the Treatment of Atopic Dermatitis

January 21, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us